Fulcrum Therapeutics (FULC) News Today

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares have been under heavy pressure after the company abruptly discontinued development of its lead and only clinical-stage program, pociredir, for sickle cell disease. The move followed U.S. FDA safety concerns about a potential class-wide cancer risk tied to PRC2-targeting agents, which effectively leaves Fulcrum without a viable clinical pipeline and has prompted the company to explore strategic alternatives, including a possible sale or merger.

Investor sentiment was further weighed down by a wave of analyst downgrades and reduced confidence in the company’s outlook:

• Positive Sentiment: Leerink Partners still sees some upside, assigning FULC a $4.00 price target, though it cut its rating to market perform.
• Neutral Sentiment: JPMorgan reaffirmed its underweight rating on Fulcrum Therapeutics, signaling continued caution rather than a new change in outlook.
• Negative Sentiment: Cantor Fitzgerald downgraded FULC from strong-buy to hold, reflecting sharply reduced confidence after the program shutdown.
• Negative Sentiment: Stifel Nicolaus cut FULC from buy to hold and set a $3.00 target, implying limited near-term upside.
• Negative Sentiment: HC Wainwright also downgraded the stock to neutral with a $3.00 target, citing the loss of the company’s only clinical asset.
• Negative Sentiment: Multiple shareholder investigations have been launched, increasing legal overhang after the sharp drop in the stock.

Overall, FULC is down sharply because the company’s lead drug program was ended due to FDA cancer-risk concerns, leaving Fulcrum with no clinical-stage assets and forcing investors to reassess its future.